News and Announcements
Richard Hopkins appointed Phylogica CEO
- Published July 19, 2013 10:48AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
PERTH, AUSTRALIA: 19 July 2013: Leading Australian peptide drug discovery company Phylogica Limited (ASX:PYC, XETRA:PH7) has appointed Dr Richard Hopkins as the company’s new Chief Executive Officer as part of a broad company strategic review. He will be appointed to the Board effective immediately.
Dr Hopkins has been with Phylogica since 2006, where he has served in variety of positions, most recently as Chief Scientific Officer (CSO). Dr Hopkins has worked with the phylomer platform for over 12 years and is a founding shareholder in Phylogica. Prior to that, he held senior research roles including with the Telethon Institute for Child Health Research, Department of Medicine at the University of Western Australia and Murdoch University.
To read the full ASX announcement, please download the document below.
Company Updates
Capital Is Flowing – Just Not to Everyone: Inside Australia’s $1.8 Billion Q1 2026
Australia’s startup ecosystem opened 2026 with a number that demanded attention. In the first three months of the year, $1.8 billion was raised across 81 venture deals and 26 accelerator rounds. That makes Q1 2026 the strongest start to a year since the 2022 boom, up 63% on Q1 2025, and more than double the […]
The control layer for the electrified home
THE MARKET SHIFT Australian households have been pulled into a real-time energy market they never knowingly signed up for. Flat electricity tariffs are disappearing. In their place: dynamic, time-of-use pricing that changes depending on when power is consumed. Electricity is now cheapest when solar floods the grid in the middle of the day — and […]
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
Backed By Leading Investment Groups and Family Offices
